Rubicon Research has informed that the Board of Directors of the Company at its meeting held today February 3, 2026: On the recommendation of the Nomination and Remuneration Committee, approved the appointment of Pradnya Saravade (DIN: 08472973) as Additional - Independent Woman Director of the Company for a period of three consecutive years effective from February 3, 2026, to February 2, 2029, subject to approval of the members of the Company; Noted the resignation of Anand Agarwal (DIN: 06481297), as a Non-Executive Director - Nominated by General Atlantic Singapore RR, effective from the close of business on February 3, 2026. Copy of the letter received from Anand Agarwal is attached; On the recommendation of the Audit Committee, approved and recommended the appointment of BNP & Associates, Practicing Company Secretaries, a peer reviewed firm (firm Registration No. P2014MH037400), as the Secretarial Auditor of the Company for an immediate term i.e., FY 2025-26 and for the remaining four years of the first five-year term from FY 2026-27 till FY 2029-30, subject to approval of members of the Company; Granted in-principle approval for the merger of KIA Health Tech, wholly owned subsidiary of the Company, with Rubicon Research Limited and their shareholders.
The above information is a part of company’s filings submitted to BSE.
